Abstract:Hepatocellular carcinoma (HCC) is the predominant form of primary liver cancer, which was the second most common cause of global cancer mortality in 2012 (<a href="#R1-8">1</a>). In the United States, mortality from liver cancer is rising faster than from any other cancer (<a href="#R2-8">2</a>). HCC is associated with chronic liver diseases such as hepatitis B or C virus infection, nonalcoholic fatty liver disease, alcoholic liver disease, and cirrhosis. HCC is most often diagnosed at a late stage, when surgical treatment is no longer an option and systemic therapy is minimally effective. Sorafenib, a multikinase inhibitor approved in 2007 for liver cancer, is the first-line standard-of-care for patients with advanced Barcelona Clinic Liver Cancer stage C HCC or intermediate Barcelona Clinic Liver Cancer stage B HCC noneligible or after failure of chemoembolization (<a href="#R3-8">3</a>). In randomized studies of advanced HCC patients with Child-Pugh A liver function, sorafenib was associated with improved survival compared to placebo in both a Western population in the SHARP trial (overall survival [OS] 10.7 vs 7.9 months, hazard ratio 0.69) and a predominantly Asian hepatitis B virus-positive population (OS 6.5 vs 4.2 months, hazard ratio 0.68) (<a href="#R4-8">4,5</a>). After progression on sorafenib, regorafenib, cabozantinib, and ramucirumab have improved survival in phase 3 trials (<a href="#R6-8">6–8</a>). Recent studies of PD-1 immune checkpoint inhibitors in HCC have demonstrated prolonged, durable responses, leading to regulatory approval in the United States (<a href="#R9-8">9,10</a>). In the front-line setting for advanced HCC, the multikinase inhibitor, lenvatinib, demonstrated noninferiority to sorafenib in the REFLECT trial (<a href="#R11-8">11</a>), but multiple drugs and combination regimens have failed to improve upon the outcomes of sorafenib monotherapy (<a href="#R12-8">12</a>).

Molecular Targeted Therapy of HCC

Sorafenib In Advanced Hepatocellular Carcinoma: Current Status And Future Perspectives

Clinical Trials in Hepatocellular Carcinoma: an Update.

The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms

Is the Era of Sorafenib Over? A Review of the Literature

Targeted therapy for hepatocellular carcinoma

Targeting Tumor-Infiltrating Ly6G+ Myeloid Cells Improves Sorafenib Efficacy in Mouse Orthotopic Hepatocellular Carcinoma.

The advanced development of molecular targeted therapy for hepatocellular carcinoma

Current Statuses of Molecular Targeted and Immune Checkpoint Therapies in Hepatocellular Carcinoma.

Combination of NK-based Immunotherapy and Sorafenib Against Hepatocellular Carcinoma.

Research hotspots and updates of diagnosis and treatment of hepatocellular carcinoma from 2017 annual meeting of the American Society of Clinical Oncology

Advances of Targeted Therapy for Hepatocellular Carcinoma

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular carcinoma: Advances in systemic therapies

Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma

Targeted Drug Delivery Strategies for the Treatment of Hepatocellular Carcinoma

Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes.

Hepatocellular carcinoma, novel therapies on the horizon

Emerging Agents and Regimens for Hepatocellular Carcinoma.

Recent treatments to Hepatocellular Carcinoma Cancer(HCC): update and outlook